CHARLOTTESVILLE, Va., /PRNewswire/ — ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer through its innovative ZielFind drug discovery platform, today announced the first patient dosed in its Phase 1/2 clinical trial. The study will evaluate ZB131 in patients with solid tumors who are either non-responsive to or ineligible for the standard …

Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with …

Manassas, VA, ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA). The work will identify and characterize novel therapeutic approaches to viruses of global health concern. Promising therapeutic candidates will be tested for efficacy with in …

Vibrent Health enhances and rebrands its consumer-facing digital health platform for data collection, recruitment and engagement of health research participants   Fairfax, VA., – Vibrent Health, a digital health technology startup dedicated to powering the future of precision health research, announced a rebranding of their participant-facing digital health research portal and mobile apps, formerly the …

CHARLOTTESVILLE, Va. (WVIR) – The University of Virginia School of Medicine is teaming up with a Charlottesville company to create a new burn treatment. Typically when skin is burned, the area surrounding it is impacted and dead, too. This new treatment is a cream that is put directly on severe wounds. “Our hope is that …

Biotechnology Innovation Organization issued a statement in opposition to senate bill 376. The statement addressed to Richard L. Saslaw, the Chairman of the Senate Committee on Commerce and Labor, explained the shortfalls of the proposed legislation and its negative impact on the innovation in bioscience. Read the entire statement below.   RE: BIO Statement in …